Understanding GOLGA6L1: A Potential Drug Target for Neurodegenerative Disorders

Target Name: GOLGA6L1

NCBI ID: G283767

GOLGA6L1

Understanding GOLGA6L1: A Potential Drug Target for Neurodegenerative Disorders

GOLGA6L1, also known as golgi autoantigen or golgin subfamily A, 6-like 1, is a protein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. It is a member of the Golgi system, which is a network of microtubules that play a key role in the transport and manipulation of vesicles and other cell membrane structures. GOLGA6L1 is a 60kDa protein that consists of 254 amino acids.

GOLGA6L1 is involved in a variety of cellular processes, including cell signaling, cytoskeletal organization, and vesicle transport. It is a potent inhibitor of the protein kinase B-36.3, which is a key regulator of cell signaling pathways that includes the T-cell receptor signaling pathway.

GOLGA6L1 has also been shown to play a role in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. For example, studies have shown that increased levels of GOLGA6L1 are associated with the development of Alzheimer's disease, and that Inhibition of GOLGA6L1 has been shown to protect against neurodegeneration in demential patients.

GOLGA6L1 is also a potential drug target for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. For example, GOLGA6L1 has been shown to be a potential therapeutic agent for the treatment of Alzheimer's disease, and is currently being investigated as a potential treatment for other neurological disorders, such as Parkinson's disease and multiple sclerosis.

In conclusion, GOLGA6L1 is a protein that is involved in a variety of cellular processes and is expressed in various tissues and organs. It is a member of the Golgi system and has been shown to play a role in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its potential as a drug target makes it an attractive target for the development of new therapies for these diseases. Further research is needed to fully understand the role of GOLGA6L1 in these processes and to develop effective treatments .

Protein Name: Golgin A6 Family Like 1

The "GOLGA6L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLGA6L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets